Acute Repetitive Seizures Market Surpass $3 Billion By 2026 | CAGR 43%

Author: Acumen Research and Consulting

Acumen Research and Consulting, a global provider of market research studies, in a latest published report titled Acute Repetitive Seizures Market (By Product: USL-261, NRL-1, AZ-002, Diastat Rectal Gel, Others ) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026”, estimates that global acute repetitive seizures market is anticipated to reach the market value of around $3 billion by 2026 and is anticipated to grow at a CAGR of around 43% in terms of revenue during the forecasting period 2018 – 2026. The global acute repetitive seizure market is anticipated to gain significant growth due to promising drugs in the pipeline. Approval from regulatory authorities such as FDA enables the companies to launch new drugs in the market thereby catering the needs of patients with rare medical conditions. This further increases the availability of therapies for such diseases. Increasing focus of research and development activities by key industry participants has led to the growing number of pipeline drugs focusing on rare diseases which will significantly widen the growth dynamics of this market.

Download Report Sample Pages For Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/968 

Increasing Prevalence of Neurological Diseases to Drive the Market

Neurological disorder is becoming common issue across the globe due to rapidly changing lifestyle and increased life expectancy. Acute repetitive seizures are life threatening neurological disorders. According to various studies, repetitive seizures may lead to neurological damage thereby increasing the risk of changes in neurological function and may lead to death. Neurological disorders are the leading cause of death and disability in the world today. In 2015, they ranked as the leading cause death group of DALYs (disability adjusted life years), comprising over 10% of global DALYs, and the second-leading cause group of deaths, comprising around 16% of global deaths. As per World Health Organization, increasing patient population suffering from prganizatio multiple sclerosis, cerebrovascular, Parkinson’s, epilepsy, and Alzheimer’s offers wide scope for acute repetitive seizures market.

Shift From Rectal To Nasal Route of Administration

Benzodiazepine, a preferred treatment for seizures can be administered through various routes of administration such as intramuscular, rectal, nasal, or buccal routes. From last few years, rectal route was preferred for administration of benzodiazepine. Rectal route of administration is found to be inconvenient in most of the patients which is one of the major aspects for patients preferring nasal route of administration over the rectal one. However, increasing demand for safe and cost-effective alternatives has led to the emergence of clinical studies for evaluating the safety and effectiveness of nasal route of administration in the form of nasal sprays. The overall event has resulted into growing number of clinical trials which is further expected to offer growth opportunities over the assessment period.

VIEW DETAIL REPORT WITH COMPLETE TOC@ https://www.acumenresearchandconsulting.com/acute-repetitive-seizures-market 

Launch Of New And Developed Products By Pharmaceutical Companies

North America accounted for the largest share of global acute repetitive seizures market and is expected to reach over USD 1000 million by 2026 growing at a CAGR of around 45%. Increase in prevalence of epilepsy and rise in awareness among people regarding treatments for seizures experienced in epilepsy are some of the key factors driving the market growth. According to the Centers for Disease Control and Prevention, in the U.S., more than 1.2% people suffered from epilepsy in 2015 which makes up to 3.4 million of the total population. Surge in the geriatric population in North America and rising frequency of repetitive seizures are other factors supporting the market growth.

Key Players

The players profiled in the report include Grupo Ferrer Internacional S.A. (ALEXZA), Neurelis, Inc., UCB S.A., and more. Key players investigating the use of nasal sprays are anticipated to lead to successful outcomes which further created opportunities for the use of oral to rectal route of administration. Some of the investigational products are anticipated to be launched in near future accelerated by increase in the number of FDA approvals and geographical expansion by market players.

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/968 

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/968 

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 415